4D Pharma PLC
LSE:DDDD
Intrinsic Value
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DDDD.
4D Pharma PLC's market capitalization is 30m GBX.
DDDD stock price is 16.66 GBX.
DDDD.
DDDD. Open DCF Valuation
DDDD. Open Relative Valuation
DDDD has upside potential of 350% compared to the average analyst price target.
Open Wall St Estimates
DDDD's Revenue has dropped by 2% over the past 12 months.
DDDD's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -128% to -116%, and is approaching profitability.
DDDD's ROE (Return on Equity) has significantly decreased in the last 3 years from -103% to -211%, and is approaching profitability.
DDDD has negative Net Debt. This means that the company has more cash and short-term investments (15m GBP) than debt (10m GBP).
DDDD's long-term assets (43m GBP) exceed its long-term liabilties (20m GBP).
DDDD has negative Operating Income for the last twelve months.
DDDD has negative Net Income for the last twelve months.
DDDD's ROE (Return on Equity) for the past 12 months is negative and is equal to -211%.
DDDD's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -116%.
DDDD's D/E (Debt to Equity) is very low and is equal to 0.42.
DDDD has negative Free Cash Flow for the last twelve months.
DDDD has negative three-year average ROE (Return on Equity): -109%. The company is not efficient at transforming stockholders' equity into net income.
DDDD has negative three-year average ROIC (Return on Invested Capital): -114%. The company is not efficient at using invested capital to generate operating income.
DDDD's short-term assets (25m GBP) exceed its short-term liabilties (5m GBP).
DDDD's Altman Z-Score is very low and is equal to -4.28.
DDDD doesn't generate enough operating income (-27m GBP) to safely cover interest payments on its debt (495k GBP).
Fundamental Analysis
4D Pharma PLC
Balance Sheet Decomposition
4D Pharma PLC
| Current Assets | 25.5m |
| Cash & Short-Term Investments | 15.5m |
| Receivables | 9.7m |
| Other Current Assets | 272k |
| Non-Current Assets | 17.4m |
| PP&E | 3.6m |
| Intangibles | 13.7m |
| Other Non-Current Assets | 199k |
| Current Liabilities | 4.9m |
| Accounts Payable | 4.8m |
| Other Current Liabilities | 80k |
| Non-Current Liabilities | 14.9m |
| Long-Term Debt | 9.9m |
| Other Non-Current Liabilities | 5m |
Earnings Waterfall
4D Pharma PLC
|
Revenue
|
522k
GBP
|
|
Operating Expenses
|
-27.1m
GBP
|
|
Operating Income
|
-26.5m
GBP
|
|
Other Expenses
|
-27.4m
GBP
|
|
Net Income
|
-54m
GBP
|
Free Cash Flow Analysis
4D Pharma PLC
What is Free Cash Flow?
DDDD Profitability Score
Profitability Due Diligence
4D Pharma PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
4D Pharma PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
DDDD Solvency Score
Solvency Due Diligence
4D Pharma PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
4D Pharma PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DDDD Price Targets Summary
4D Pharma PLC
According to Wall Street analysts, the average 1-year price target for
DDDD
is 75 GBX
.
Shareholder Return
DDDD Price
4D Pharma PLC
| Average Annual Return | 2.59% |
| Standard Deviation of Annual Returns | 35.83% |
| Max Drawdown | -91% |
| Market Capitalization | 30m GBX |
| Shares Outstanding | 180 300 967 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
4D Pharma PLC
Country
Industry
Market Cap
Dividend Yield
Description
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. The company uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. The company is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
You don't have any saved screeners yet
